BCL2 and lymphoma: This molecule shows synergy with select BH3‐mimetic drugs in killing cancer cells, and in particular with the BCL2 inhibitor venetoclax against the aggressive double‐hit lymphoma subtype, with promising antitumoral effects in preclinical models.